C.R. Bard Inc. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component C.R. Bard, Inc. (NYSE:BCR) will unveil its latest earnings on Tuesday, January 31, 2012. C.R. Bard designs, makes, and sells diagnostic, medical, surgical, and patient care devices.

C.R. Bard, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.68 per share, a rise of 9.1% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 13.9% versus last year to $6.38.

Past Earnings Performance: Last quarter, the company topped estimates by 0 cents, coming in at net income of $1.62 per share against a mean estimate of profit of $1.60. The company fell in line with estimates in the second quarter.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $748.6 million in revenue this quarter, a rise of 4.4% from the year ago quarter. Analysts are forecasting total revenue of $2.89 billion for the year, a rise of 6.3% from last year’s revenue of $2.72 billion.

Analyst Ratings: Analysts seem relatively indifferent about C.R. Bard with 15 of 19 analysts surveyed maintaining a hold rating.

A Look Back: In the third quarter, profit rose 2% to $130.1 million ($1.46 a share) from $127.5 million ($1.34 a share) the year earlier, exceeding analyst expectations. Revenue rose 6% to $719.2 million from $678.4 million.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 7.6% in the second quarter from the year earlier, climbed 7.6% in the first quarter from the year-ago quarter and 5.9% in the fourth quarter of the last fiscal year.

Competitors to Watch: Teleflex Incorporated (NYSE:TFX), Covidien plc (NYSE:COV), Boston Scientific Corp. (NYSE:BSX), Merit Medical Systems, Inc. (NASDAQ:MMSI), AngioDynamics, Inc. (NASDAQ:ANGO), Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), Theragenics Corporation (NYSE:TGX), Rochester Medical Corp. (NASDAQ:ROCM), CONMED Corporation (NASDAQ:CNMD), and Becton, Dickinson and Co. (NYSE:BDX).

Stock Price Performance: During November 25, 2011 to January 25, 2012, the stock price had risen $10.32 (12.4%) from $83.19 to $93.51. The stock price saw one of its best stretches over the last year between January 13, 2012 and January 25, 2012 when shares rose for eight-straight days, rising 9.7% (+$8.25) over that span. It saw one of its worst periods between November 15, 2011 and November 23, 2011 when shares fell for seven-straight days, falling 6.3% (-$5.55) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com